organon & co. - OGN
OGN
Close Chg Chg %
10.83 0.30 2.73%
Closed Market
11.12
+0.30 (2.73%)
Volume: 2.93M
Last Updated:
Apr 17, 2025, 3:59 PM EDT
Company Overview: organon & co. - OGN
OGN Key Data
| Open $10.93 | Day Range 10.88 - 11.22 |
| 52 Week Range 10.75 - 23.10 | Market Cap $2.87B |
| Shares Outstanding 257.95M | Public Float 257.08M |
| Beta 0.69 | Rev. Per Employee N/A |
| P/E Ratio 3.34 | EPS $3.36 |
| Yield 1,007.19% | Dividend $0.28 |
| EX-DIVIDEND DATE Feb 24, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.42M |
OGN Performance
| 1 Week | -0.54% | ||
| 1 Month | -27.75% | ||
| 3 Months | -29.35% | ||
| 1 Year | -37.60% | ||
| 5 Years | N/A |
OGN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About organon & co. - OGN
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
OGN At a Glance
Organon & Co.
30 Hudson Street
Jersey City, New Jersey 07302
| Phone | 1-551-430-6900 | Revenue | 6.40B | |
| Industry | Pharmaceuticals: Major | Net Income | 864.00M | |
| Sector | Health Technology | 2024 Sales Growth | 2.235% | |
| Fiscal Year-end | 12 / 2025 | Employees | 10,000 | |
| View SEC Filings |
OGN Valuation
| P/E Current | 3.335 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 4.475 |
| Price to Sales Ratio | 0.604 |
| Price to Book Ratio | 8.149 |
| Price to Cash Flow Ratio | 4.118 |
| Enterprise Value to EBITDA | 6.889 |
| Enterprise Value to Sales | 1.91 |
| Total Debt to Enterprise Value | 0.739 |
OGN Efficiency
| Revenue/Employee | 640,300.00 |
| Income Per Employee | 86,400.00 |
| Receivables Turnover | 4.294 |
| Total Asset Turnover | 0.509 |
OGN Liquidity
| Current Ratio | 1.60 |
| Quick Ratio | 1.114 |
| Cash Ratio | 0.248 |
OGN Profitability
| Gross Margin | 58.02 |
| Operating Margin | 23.395 |
| Pretax Margin | 12.603 |
| Net Margin | 13.494 |
| Return on Assets | 6.868 |
| Return on Equity | 429.851 |
| Return on Total Capital | 9.087 |
| Return on Invested Capital | 9.468 |
OGN Capital Structure
| Total Debt to Total Equity | 1,914.407 |
| Total Debt to Total Capital | 95.036 |
| Total Debt to Total Assets | 68.972 |
| Long-Term Debt to Equity | 1,900.847 |
| Long-Term Debt to Total Capital | 94.363 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Organon & Co. - OGN
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 6.36B | 6.17B | 6.26B | 6.40B | |
Sales Growth
| -21.44% | -2.92% | +1.44% | +2.24% | |
Cost of Goods Sold (COGS) incl D&A
| 2.38B | 2.28B | 2.52B | 2.69B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 195.00M | 212.00M | 236.00M | 277.00M | |
Depreciation
| 92.00M | 96.00M | 120.00M | 132.00M | |
Amortization of Intangibles
| 103.00M | 116.00M | 116.00M | 145.00M | |
COGS Growth
| -28.77% | -4.28% | +10.31% | +6.88% | |
Gross Income
| 3.98B | 3.89B | 3.75B | 3.71B | |
Gross Income Growth
| -16.29% | -2.11% | -3.75% | -0.88% | |
Gross Profit Margin
| +62.55% | +63.07% | +59.84% | +58.02% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.11B | 2.17B | 2.42B | 2.22B | |
Research & Development
| 443.00M | 471.00M | 528.00M | 469.00M | |
Other SG&A
| 1.66B | 1.70B | 1.89B | 1.75B | |
SGA Growth
| +6.90% | +3.28% | +11.31% | -8.43% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 96.00M | 149.00M | 70.00M | 93.00M | |
EBIT after Unusual Expense
| 1.78B | 1.57B | 1.26B | 1.41B | |
Non Operating Income/Expense
| 11.00M | (26.00M) | (57.00M) | (69.00M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 258.00M | 422.00M | 527.00M | 529.00M | |
Interest Expense Growth
| +4,200.00% | +63.57% | +24.88% | +0.38% | |
Gross Interest Expense
| 258.00M | 422.00M | 527.00M | 529.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.53B | 1.12B | 673.00M | 807.00M | |
Pretax Income Growth
| -42.95% | -26.62% | -40.02% | +19.91% | |
Pretax Margin
| +24.04% | +18.17% | +10.75% | +12.60% | |
Income Tax
| 178.00M | 205.00M | (350.00M) | (57.00M) | |
Income Tax - Current - Domestic
| 31.00M | 51.00M | 48.00M | 32.00M | |
Income Tax - Current - Foreign
| 435.00M | 172.00M | 87.00M | 71.00M | |
Income Tax - Deferred - Domestic
| (68.00M) | (40.00M) | (57.00M) | (58.00M) | |
Income Tax - Deferred - Foreign
| (220.00M) | 22.00M | (428.00M) | (102.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 1.35B | 917.00M | 1.02B | 864.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 1.35B | 917.00M | 1.02B | 864.00M | |
Net Income Growth
| -37.45% | -32.12% | +11.56% | -15.54% | |
Net Margin Growth
| +21.24% | +14.85% | +16.33% | +13.49% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 1.35B | 917.00M | 1.02B | 864.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.35B | 917.00M | 1.02B | 864.00M | |
EPS (Basic)
| 5.3283 | 3.6091 | 4.008 | 3.3613 | |
EPS (Basic) Growth
| -37.56% | -32.27% | +11.05% | -16.14% | |
Basic Shares Outstanding
| 253.55M | 254.08M | 255.24M | 257.05M | |
EPS (Diluted)
| 5.3283 | 3.5937 | 3.9919 | 3.334 | |
EPS (Diluted) Growth
| -37.56% | -32.55% | +11.08% | -16.48% | |
Diluted Shares Outstanding
| 253.55M | 255.17M | 256.27M | 259.15M | |
EBITDA
| 2.07B | 1.93B | 1.56B | 1.77B | |
EBITDA Growth
| -29.67% | -6.58% | -19.06% | +13.56% | |
EBITDA Margin
| +32.50% | +31.28% | +24.96% | +27.72% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 20.00 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.908 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 3.845 | |
| Last Quarter’s Earnings | 0.90 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.11 | Next Fiscal Year Estimate | 3.994 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 6 | 5 |
| Mean Estimate | 0.91 | 0.90 | 3.85 | 3.99 |
| High Estimates | 0.97 | 0.95 | 4.23 | 4.33 |
| Low Estimate | 0.79 | 0.77 | 3.66 | 3.70 |
| Coefficient of Variance | 8.03 | 8.37 | 5.28 | 6.44 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 2 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 2 | 4 | 4 |
| UNDERWEIGHT | 2 | 1 | 1 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Organon & Co. - OGN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Organon & Co. - OGN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Carrie Smith Cox Director | 47,060 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Deborah R. Leone Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Grace Puma Whiteford Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Philip O. Ozuah Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Cynthia M. Patton Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | R. Alan B. Ezekowitz Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Shalini Sharp Director | 36,784 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Helene D. Gayle Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Martha E. McGarry Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Robert A. Essner Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Rochelle B. Lazarus Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | 49,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | 48,237 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 945,927.57 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Matthew M. Walsh Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Matthew M. Walsh Chief Financial Officer | 88,326 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 1,732,072.86 |
| May 8, 2024 | Matthew M. Walsh Chief Financial Officer | 92,419 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | 52,253 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | 50,664 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 993,521.04 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |